PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.07
Negative OCF/share while TRAW has 6060.75. Joel Greenblatt would question the viability of operations in comparison.
-0.09
Negative FCF/share while TRAW stands at 6042.54. Joel Greenblatt would demand structural changes or cost cuts.
-37.64%
Negative ratio while TRAW is 0.30%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.
0.47
Positive ratio while TRAW is negative. John Neff would note a major advantage in real cash generation.
No Data
No Data available this quarter, please select a different quarter.